Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
National Cancer Institute (NCI)
AstraZeneca
Mayo Clinic
STORM Therapeutics LTD
Neonc Technologies, Inc.
Ipsen
Bristol-Myers Squibb
Radiopharm Theranostics, Ltd
Tizona Therapeutics, Inc
Aulos Bioscience, Inc.
Genentech, Inc.
DualityBio Inc.
MacroGenics
Innate Pharma
Elephas
OncoNano Medicine, Inc.
Compass Therapeutics
Mayo Clinic
Memorial Sloan Kettering Cancer Center
Alpha Tau Medical LTD.
Alpha Tau Medical LTD.
LG Chem
West China Hospital
DualityBio Inc.
M.D. Anderson Cancer Center
Guardant Health, Inc.
Medicenna Therapeutics, Inc.
Iovance Biotherapeutics, Inc.
University of Palermo
Rapa Therapeutics LLC
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Vyriad, Inc.
Providence Health & Services
University of Pittsburgh
Alpha Tau Medical LTD.
CJ Bioscience, Inc.
Simcha IL-18, Inc.
Presage Biosciences
IO Biotech